The STING agonist cdGMP reprograms macrophages toward an anti-tumor phenotype, and treatment with immuno-MSN (cdGMP) was observed to delay tumor growth and increase dendritic cells (CD11c+) and circulating CD8+ T cells [44]. This evidence concerns the gene CD8A and neoplasm.